Biodegradable long circulating cellular carrier for antimalarial drug pyrimethamine
Source abstract
Abstract
OBJECTIVE: The objective of the present study was to develop targeted engineered nanoerythrosomes based intravenous formulation of antimalarial drug pyrimethamine. MATERIAL AND METHODS: The nanoerythrosomes formulation was developed by sonication method and optimized for effective drug loading at variable drug concentration, surface morphology, viscosity and sedimentation volume. RESULTS: The in vitro drug release of formulated product was found to be delayed after 8 hours, having good stability at 4 ± 1°C and showing controlled in vivo release. Tissue distribution studies showed higher accumulation of drug in the liver (18.71 ± 1.4 μg/ml) (P < 0.05) at 1 hour in case of pyrimethamine-loaded nanoerythrosomes as compared to that in free drug (12.82 ± 0.7 μg/ml). Higher amount of drug, i.e. 14.18 ± 0.9 μg/ml (P < 0.05), was found after 24 hours in the liver in case of pyrimethamine-loaded nanoerythrosomes as compared to free drug concentration of 9.72 ± 0.5 μg/ml). DISCUSSION: Data showed that developed pyrimethamine-loaded nanoerythrosomes hold promise for targeting and controlling the release of drug and for improving treatment of malaria when they are combined with rapid acting antimalarials such as artemisinin. CONCLUSION: A decrease in the concentration of pyrimethamine in kidneys and lungs after 24 hours was observed as compared to that observed after 1 hour, showing no or little involvement of these organs in the clearance of drug-loaded nanoerythrosomes.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Silymarin and Mushroom Poisoning · Advancements in Transdermal Drug Delivery · Inhalation and Respiratory Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (23)
Show source-provided references
1. Al-Achi A · Drug Dev Ind Pharm · 1993 · 19 · 67310.3109/03639049309062974 ↗
2. Bray PG · Curr Top Microbiol Immunol · 2005 · 295 · 3
3. Breman JG · Am J Trop Med Hyg · 2004 · 71 · 110.4269/ajtmh.2004.71.2_suppl.0700001 ↗
4. Breman JG · Am J Trop Med Hyg · 2001 · 64 · 110.4269/ajtmh.2001.64.1 ↗
5. Budawai S · 2003 · 1747
6. DeLoach JR · Am J Vet Res · 1982 · 43 · 221010.2460/ajvr.1982.43.12.2210 ↗
7. Fullerton DS. 1982. Wilson & Gisvold's text book of organic medical and pharmaceutical chemistry. Philadelphia: Lippincott, pp. 205–206.
8. 10.1023/A:101604902766110.1023/A:1016049027661 ↗
9. Hamidi M · Drug Delivery · 2001 · 8 · 22310.1080/107175401317245903 ↗
10. Iher GM · Proc Natl Acad Sci USA · 1973 · 70 · 266310.1073/pnas.70.9.2663 ↗
11. Jain NK. 2003. Advances in controlled and novel drug delivery. New Delhi: CBS Publisher and Distributor, pp. 339–340.
12. Jain S · Ind Drugs · 1995 · 32 · 471
13. Jain S · Die Pharmazie · 1998 · 53 · 5
14. Jain S · Ind Drugs · 1995 · 32 · 471
15. Mital A · Curr Med Chem · 2007 · 14 · 75910.2174/092986707780090927 ↗
16. Minzi OMS · Chromat B · 2005 · 814 · 17910.1016/j.jchromb.2004.10.049 ↗
17. Moorjani M · Anticancer Res · 1996 · 16 · 2831
18. Talwar N · J Control Rel · 1992 · 20 · 13310.1016/0168-3659(92)90159-O ↗
19. Talwar N · Drug Dev Ind Pharm · 1992 · 18 · 179910.3109/03639049209040903 ↗
20. Updike SJ · J Lab Clin Med · 1983 · 101 · 679
21. Vangapandu S · Med Res Rev · 2007 · 27 · 6510.1002/med.20062 ↗
22. WHO and UNICEF · 2005
23. Wilairatana P · Arch Med Res · 2002 · 33 · 41610.1016/S0188-4409(02)00371-5 ↗